Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer

Trial Profile

Phase II Study of Pembrolizumab and Capecitabine for Advanced Triple Negative and Hormone-Refractory Breast Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Capecitabine (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 06 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 07 Mar 2017 Planned initiation date changed from 1 Feb 2017 to 1 Apr 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top